BioCentury | Jul 20, 2015
Strategy

Window to gene therapy

Biogen Inc .'s recent deal with Applied Genetic Technologies Corp. is mainly a play to gain hands-on experience developing and manufacturing gene therapies while building its own gene therapy research unit. Early last year, after...
BioCentury | Apr 15, 2013
Company News

IntroGene sales and marketing update

...retinoblasts with an E1 mini gene of human adenovirus type 5. Price was not disclosed. IntroGene B.V....
BioCentury | Apr 15, 2013
Company News

Introgen management update

Introgen Therapeutics Inc. , Austin, Texas Business: Cancer Hired: Shawn Gallagher, vice president of manufacturing; formerly director of operations at Magenta Corp. WIR Staff cancer...
BioCentury | Apr 15, 2013
Company News

Introgen, Rhone-Poulenc Rorer deal

Introgen received a $5 million time-based equity investment from RPR under the terms of its collaboration with RPR GenCell for development of p53 tumor suppressor gene therapy. GenCell will begin Phase I trials of p53...
BioCentury | Apr 11, 2011
Finance

A Remembrance: The venture capitalist as artist

...for the first time in 1993 when we were raising funds for Crucell (still called IntroGene...
BioCentury | May 31, 2010
Finance

Performance Counts

...between IntroGene BV and Tibotec NV. The company's platform was based on adenoviral libraries from IntroGene...
BioCentury | Feb 8, 2010
Product Development

Checking the boxes in gene therapy

Amsterdam Molecular Therapeutics thinks its Glybera represents the right combination of vector, gene and disease setting to become the first gene therapy to be approved outside of China. The European Medicines Agency now has accepted...
BioCentury | Aug 10, 2009
Clinical News

Contusugene ladenovec regulatory update

EMEA said Introgen withdrew an MAA for Contusugene ladenovec to treat squamous cell carcinoma of the head and neck (SCCHN). According to the agency, Introgen withdrew the application based on its "difficult financial situation." The...
BioCentury | Apr 20, 2009
Finance

Cancer vaccine uplift

Cancer vaccine uplift Company 4/17 cls % wk chg Dendreon Corp. (NASDAQ:DNDN) $17.99 186% Prima Biomed Ltd. (ASX:PRR) A$0.03 100% Oxford BioMedica plc (LSE:OXB) 11.25p 72% Biovest International Inc. (Pink: BVTI) (majority-owned by Accentia Biopharmaceuticals...
BioCentury | Jan 5, 2009
Clinical News

Advexin regulatory update

EMEA said Introgen withdrew an MAA for Advexin to treat Li-Fraumeni syndrome (LFS) cancers. According to the agency, Introgen withdrew the application based on the company's "marketing strategy." Advexin, an adenovirus p53 tumor suppressor gene...
Items per page:
1 - 10 of 312
BioCentury | Jul 20, 2015
Strategy

Window to gene therapy

Biogen Inc .'s recent deal with Applied Genetic Technologies Corp. is mainly a play to gain hands-on experience developing and manufacturing gene therapies while building its own gene therapy research unit. Early last year, after...
BioCentury | Apr 15, 2013
Company News

IntroGene sales and marketing update

...retinoblasts with an E1 mini gene of human adenovirus type 5. Price was not disclosed. IntroGene B.V....
BioCentury | Apr 15, 2013
Company News

Introgen management update

Introgen Therapeutics Inc. , Austin, Texas Business: Cancer Hired: Shawn Gallagher, vice president of manufacturing; formerly director of operations at Magenta Corp. WIR Staff cancer...
BioCentury | Apr 15, 2013
Company News

Introgen, Rhone-Poulenc Rorer deal

Introgen received a $5 million time-based equity investment from RPR under the terms of its collaboration with RPR GenCell for development of p53 tumor suppressor gene therapy. GenCell will begin Phase I trials of p53...
BioCentury | Apr 11, 2011
Finance

A Remembrance: The venture capitalist as artist

...for the first time in 1993 when we were raising funds for Crucell (still called IntroGene...
BioCentury | May 31, 2010
Finance

Performance Counts

...between IntroGene BV and Tibotec NV. The company's platform was based on adenoviral libraries from IntroGene...
BioCentury | Feb 8, 2010
Product Development

Checking the boxes in gene therapy

Amsterdam Molecular Therapeutics thinks its Glybera represents the right combination of vector, gene and disease setting to become the first gene therapy to be approved outside of China. The European Medicines Agency now has accepted...
BioCentury | Aug 10, 2009
Clinical News

Contusugene ladenovec regulatory update

EMEA said Introgen withdrew an MAA for Contusugene ladenovec to treat squamous cell carcinoma of the head and neck (SCCHN). According to the agency, Introgen withdrew the application based on its "difficult financial situation." The...
BioCentury | Apr 20, 2009
Finance

Cancer vaccine uplift

Cancer vaccine uplift Company 4/17 cls % wk chg Dendreon Corp. (NASDAQ:DNDN) $17.99 186% Prima Biomed Ltd. (ASX:PRR) A$0.03 100% Oxford BioMedica plc (LSE:OXB) 11.25p 72% Biovest International Inc. (Pink: BVTI) (majority-owned by Accentia Biopharmaceuticals...
BioCentury | Jan 5, 2009
Clinical News

Advexin regulatory update

EMEA said Introgen withdrew an MAA for Advexin to treat Li-Fraumeni syndrome (LFS) cancers. According to the agency, Introgen withdrew the application based on the company's "marketing strategy." Advexin, an adenovirus p53 tumor suppressor gene...
Items per page:
1 - 10 of 312